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Abstract 
Among numerous reported biochemical effects the lithium-inhibitable enzyme inositol-
monophosphatase (IMPase) remains a viable target for lithium's therapeutic mechanism of action. 
Calbindin-D28k (calbindin) interacts with IMPase enhancing its activity. In the present study in silico 
modeling of IMPase-calbindin binding using the program MolFit indicated that the 55-66 amino acid 
segment of IMPase anchors calbindin via Lys59 and Lys61 with a glutamate in between (Lys-Glu-Lys 
motif). The model further suggested that the Lys-Glu-Lys motif interacts with residues Asp24 and 
Asp26 of calbindin. Indeed, we found that differently from wildtype calbindin, IMPase was not 
activated by mutated calbindin in which Asp24 and Asp26 were replaced by alanine. Calbindin's effect 
was significantly reduced by a peptide with the sequence of amino acids 58-63 of IMPase (peptide 1) 
and by six amino-acid peptides including at least part of the Lys-Glu-Lys motif. The three amino-acid 
peptide Lys-Glu-Lys or five amino-acid peptides containing this motif were ineffective. 
Intracerebroventricular administration of peptide 1 resulted in a significant antidepressant-like reduced 
immobility in the Porsolt forced swim test (FST) compared with mice treated with a scrambled peptide 
or artificial cerebrospinal fluid. Based on the sequence of peptide 1, and to potentially increase the 
peptide's stability, cyclic and linear pre-cyclic analog peptides were synthesized. One cyclic and one 
linear pre-cyclic analog peptides exhibited an inhibitory effect on calbindin-activated brain IMPase 
activity in vitro. These findings may lead to the development of molecules capable of inhibiting IMPase 
activity at an alternative site than that of lithium. 
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 Introduction 
Inositol monophosphatase (IMPase) remains a viable target for the therapeutic effect of lithium as a 
mood stabilizer (1, 2). IMPase has an important role in the phosphatidylinositol (PI) signaling system 
since it catalyzes the dephosphorylation of myo-inositol monophosphates to free myo-inositol (3). It has 
been shown that therapeutically-relevant lithium concentrations (0.5-1.5 mM) exert an uncompetitive 
inhibition on IMPase with a Ki of 0.1 to 1.0 mM, probably by binding to a Mg2+-binding site of the 
enzyme (3-5). Reduced activity of IMPase may lead to depletion of intracellular free myo-inositol 
which is required for the re-synthesis of the signaling precursor PI and thus may dampen overactivity of 
this signaling cascade (6). This possibility is known as the inositol depletion hypothesis of the 
mechanism of lithium's mood stabilizing effect (7): While several studies question the relevance of this 
hypothesis (8) other results support it (1, 9, 10). 
  Based on lithium's inhibition of IMPase activity several pharmaceutical companies have tried to 
synthesize IMPase inhibitors such as bisphosphonates (11) and terpenoid and tropolone analogues (12) 
targeted at the substrate site of the enzyme. However, their further development to clinical mood 
stabilizers was limited for a variety of reasons (11).  
Calbindin D28k (calbindin), a member of the vitamin-D-dependent calcium-binding proteins, was 
found to activate IMPase in vitro (13). It was shown that calbindin binds a specific amino-acid sequence 
of IMPase (residues 55-66) enhancing its activity by several fold (13).  Calbindin is common in neurons 
of the hippocampus (14), temporal cortex (15), anterior cingulate cortex (16) and prefrontal cortex (17) 
constituting about 1% of total brain soluble protein (18). Calbindin shapes postsynaptic calcium signals 
(19-21), and is involved in synaptic plasticity (22). Schmidt et al (21) have shown in situ that calbindin's 
interaction with IMPase occurs in spines and dendrites but not in axons of cerebellar Purkinje neurons 
which depend on PI signaling for synaptic integration. The interaction is enhanced by synaptic activity 
and results in calbindin's immobilization by membrane- or cytoskeleton-bound IMPase (21).  We have 
previously shown that addition of recombinant human calbindin increases IMPase activity of 
postmortem human prefrontal cortex crude homogenate by 3.5 fold (23).  Given the fact that calbindin 
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is highly abundant in brain tissue it is conceivable to assume that in-vivo, brain IMPase is constitutively 
bound to calbindin and that this protein-protein interaction is involved in PI-mediated synapse function. 
In the present study we explored the possibility to inhibit IMPase activity at the calbindin-IMPase 
interaction site using competitive peptides which would interfere with the activating interaction. Four 
six amino-acid linear peptides rationally designed based on in silico modeling of the interaction 
inhibited calbindin-activated brain IMPase activity in vitro. One of these peptides was tested in vivo in 
an animal model of depression, the Porsolt forced swim test (FST), and exhibited an antidepressant-like 
reduced immobility. Based on the backbone of this linear peptide, cyclic and linear pre-cyclic analog 
peptides were synthesized to potentially increase the peptide's stability. One cyclic peptide and one 
linear pre-cyclic peptide exhibited an inhibitory effect on calbindin-enhanced brain IMPase activity in 
vitro. These findings may lead to the development of molecules capable of inhibiting IMPase activity at 
an alternative site than that of lithium.  
 
Materials and Methods 
Modeling the structure of the complex between IMPase and calbindin  
Figure 1, showing the three dimensional structure of IMPase and of the complex of IMPase with 
calbindin, was produced using the program PyMol (24).  The crystal structure of IMPase (PDB entry 
2bji) and the NMR structure of calbindin (PDB entry 2g9b) were used to model the structure of the 
complex using the protein-protein docking program MolFit (25). For a full and detailed description of 
the modeling process please refer to the Supplementary Information.   
Peptides design based on the modeled complex 
We used the resulting model as a basis for designing eleven short linear peptides (Table 1). Peptide 
1, a 6-mer peptide, was composed of an identical sequence as residues 58-63 of IMPase (Ile-Lys-Glu-
Lys-Tyr-Pro). These six amino acids are the central sequence of the previously reported 12 amino acid 
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segment (residues 55-66) of IMPase shown to interact with calbindin (18). Furthermore, this specific 6-
mer peptide is fully conserved between mouse and human. This segment includes Lys59 and Lys61, 
separated by Glu60 designated the Lys-Glu-Lys motif. Additional designed three 6-mer peptides 
included at least part of the Lys-Glu-Lys motif (peptides 2-4). In peptide 2 we permutated Glu60 to 
alanine. Peptides 3 and 4 are similar to peptide 1 but in each peptide one of the Lys residues in the Lys-
Glu-Lys motif was permutated to alanine. Four other 6-mer peptides included only one or none of the 
amino acids Lys or Glu of the Lys-Glu-Lys motif (peptides 5-8). In peptide 5 one of the lysine residues 
and Ile58 were permutated to histidine and serine, respectively, and the whole sequence has been 
scrambled. Peptide 6 was composed of the same sequence as peptide 1 but the two lysine residues were 
permutated into alanine. Peptide 7 was also composed of the same sequence as peptide 1 but the whole 
Lys-Glu-Lys motif has been permutated to three alanine residues (Ala-Ala-Ala). Peptide 8 was a 
random 6-mer peptide containing two lysine residues, albeit, separated by two, rather than a single 
residue, none of which was a glutamate. Two 5-mer peptides lacking the carboxyterminal proline 
included either the Lys-Glu-Lys motif (peptide 9) or Lys-Ala-Lys replacement (peptide 10). One 3-mer 
peptide was composed of the Lys-Glu-Lys motif only (peptide 11). The peptides were custom-
synthesized by GeneScript Corporation, Scotch Plains, NJ (Table 1).  
Mutated calbindin 
Human recombinant calbindin was mutated at the Israel Structural Proteomics Center (ISPC), the 
Weizmann Institute of Science (Rehovot, Israel) to exchange residues Asp24 and Asp26 into alanine 
(calbindin D24A, D26A). Calbindin D24A, D26A was generated by site-directed mutagenesis based on 
the QuikChange site-directed mutagenesis protocol of Stratagene (La Jolla, CA). For a full and detailed 
description of the preparation of mutated calbindin please refer to the Supplementary Information.  
IMPase activity     
IMPase activity in mouse brain homogenates was measured as previously described (26). Inorganic 
phosphate liberated from inositol-1-phosphate was quantified spectrophotometrically in an ELISA 
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reader (iEMS, Labsystems, Helsinki, Finland) using the malachite green color reagent.  To study the 
effect of the synthetic peptides on the enhancing interaction between calbindin and IMPase the reaction 
was carried out in the presence of 20 μM human recombinant calbindin (27) (produced by PPS, 
Rehovot, Israel, using the plasmid kindly donated by S. Linse, Lund, Sweden) and in the presence or 
absence of 10 μM of each of the peptides.  In order to distinguish IMPase activity from non-specific 
phosphatases the reaction was carried out in the presence and absence of 30 mM LiCl. LiCl is a specific 
inhibitor of this enzyme (3) and at this concentration totally inhibits IMPase activity.  The enzyme 
activity was calculated as the difference between the activity values in the absence and in the presence 
of LiCl. Values were normalized to the mean of the control values in each run.  
Preparation of liposome-trapped peptides   
Liposomes (Liposome kit: Lipid mixtures for the preparation of liposomes, Sigma, St. Louis, MO) 
were prepared according to the manufacturer's instructions with modification as follows. The 
reconstituted liposomes were diluted 1:5 with artificial CSF (aCSF, consisting of 145 mM NaCl, 1.2 
mM CaCl2, 2.7 mM KCl and 1 mM MgCl2) or one of the peptides dissolved in aCSF followed by a 
short sonication for five seconds using a Polytron cell homogenizer (Heat System Ultrasonic INC, 
Newtown, CT) at 4oC and 50% power capacity.    
Animals  
Mice used for behavioral and pharmacological studies were housed and kept under 12:12 h 
light/dark cycles (lights on at 8:00 AM) in a room with constant temperature (22ºC) and food and water 
ad libitum.  All experiments were conducted during the light phase of the light/dark cycle.  Protocols of 
the experiments were approved by the Ben-Gurion University of the Negev (Beer-Sheva, Israel) 
committee for the ethical care and use of animals in research and conducted according to NIH 
guidelines.  
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Effect of specific peptides in the Porsolt forced swim test 
Eight weeks old ICR male mice (Harlan, Jerusalem, Israel) were anesthetized with 20% isoflurane 
and a screw guide was implanted 0.2-0.3 mm posterior to the bregma 1 mm lateral to midline, above 
the lateral ventricle. The incision was closed and the mice were put back in their cage with 5% 
lidocaine administered locally and 1.25 g dipyrone/200 ml in the drinking water was given for 
analgesia. After a week of recovery, mice were anesthetized and injected through the guide screw with 
5 µl of liposomes containing the test peptide (peptide 1 IKEKYP: 50 nmoles, n=13, peptide 5 
SYEHKP: 50 nmoles, n=5) or aCSF as control (n=8). Three hours later mice were placed for 6 minutes 
in a glass cylinder (height 20 cm, diameter 12 cm) filled with water at a temperature of 24 ± 1ºC to a 
height of 13 cm (such that the mouse could not touch the bottom or climb out of the cylinder at any 
point). The session was digitally recorded for later analysis.  Analysis of the digitally recorded behavior 
was done by an experimenter who was blind to a mouse treatment.  The duration of immobility was 
monitored during the last 4 min of the 6-min test.  Immobility period was defined as the time spent by 
the animal floating without struggling and making only those movements necessary to keep its head 
above the water. In addition, another group of mice received a single i.p. injection of 15 mg⁄kg 
imipramine hydrochloride (Sigma, St. Louis, MO) 30 min before the test and were used as a positive 
control of an antidepressant effect.  After the test the screw location was confirmed by dye injection. 
Synthesis and measurement of metabolic stability of cyclic and linear pre-cyclic analog peptides  
Synthesis of cyclic and linear pre-cyclic analog peptides was based on the concept of backbone 
cyclization (28, 29). The metabolic stability of cyclic peptide 1 was measured using rat brush border 
membrane vesicles as previously described (30). For a full and detailed description of these 
methodologies please refer to the Supplementary Information.   
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Results 
A modeled structure of the complex between IMPase and calbindin suggests that residues Lys59, 
Glu60 and Lys 61 of IMPase play a major role in the interaction  
A plausible model of the interaction between IMPase and calbindin was obtained using the docking 
program MolFit followed by energy minimization. Residues 55-66 of IMPase comprise the segment 
which has been shown to interact with calbindin (13). In the docking procedure residues 55-66 of 
IMPase were placed in the interface between the two proteins. In contrast, no restraints were imposed 
on the interacting surface of calbindin. In the modeled complex depicted in Figure 1 optimal binding 
requirements were deduced. IMPase binds a groove formed by the N- and C-terminal domains of 
calbindin and interacts with the calcium binding loops. The 55-66 segment of IMPase anchors calbindin 
via two lysine residues, Lys59 and Lys61, whereas the residue in between, glutamate (Glu60), is 
hydrated.  The modeled complex further indicates several possible hydrogen bonds between residues 
55-66 of IMPase and calbindin.  Nξ (the side chain nitrogen atom) of Lys59 of IMPase is hydrogen 
bonded to calbindin via three oxygen atoms, the Oδ1 (a side chain oxygen atom) of Asp24, and the 
main chain carbonyl oxygen atoms of Asp24 and Asp26. The distances between Nξ and each of Oδ1, 
the carbonyl oxygen of Asp24 and the carbonyl oxygen of Asp26 are 2.70Å, 2.74Å and 2.77Å, 
respectively.  Additionally, Nξ of Lys61 of IMPase is hydrogen bonded to calbindin via Oδ1 of Asn158 
(2.85Å) and via Oδ1 of Asp155 (2.91Å); Nε2 (a nitrogen atom in the heterocyclic side chain) of His65 
of IMPase is involved in a hydrogen bond to Oδ2 of Asp280 of calbindin.  
Specific linear peptides inhibit calbindin-activated IMPase  
The effect of specifically designed linear peptides was validated by in vitro IMPase activity 
measurements in the presence of calbindin. As shown in Figure 2 IMPase activity of mouse brain crude 
homogenate is increased by 1.9 ± 1.0 (S.E.M.) fold in the presence of 20 μM human recombinant 
calbindin. When 10 μM of peptide 1 were added to the reaction mixture the effect of calbindin on 
IMPase activity was strongly reduced. Peptides 2 through 4, which included the Lys-Glu-Lys motif or 
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part of it, inhibited the activating interaction similarly to peptide 1 (Figure 2A). Peptides 5 through 8, 
which included only one or none of the amino acids Lys or Glu, did not interfere with the enhancement 
of IMPase activity by calbindin (Figure 2B). Peptides 9 and 10, comprised of five amino acids and 
peptide 11 comprised of three amino acids which contained either an intact Lys-Glu-Lys motif or a Lys-
Ala-Lys replacement did not interfere with the enhancement of IMPase activity by calbindin (Figure 
2C).  Our results suggest that peptides 1 through 4 but not peptides 5 through 11 contain the preferred 
residues that optimize the competition with IMPase on the interaction with calbindin.  
The inhibitory effect of peptide 1 on calbindin-activated IMPase was also demonstrated with 
postmortem human brain crude homogenate. Human recombinant calbindin increased human brain 
IMPase activity by 3 fold and peptide 1 abolished this effect (data not shown). 
To control for a possible nonspecific effect of linear short peptides on IMPase activity the enzyme's 
activity in the presence of peptide 1 (but in the absence of calbindin) was assessed. Peptide 1 did not 
affect the basal activity of IMPase. We further assessed possible protease activity in the homogenate 
and the possibility that prior interaction between IMPase and calbindin prevents interference by the 
active peptides. To this end we preincubated calbindin with the homogenate for 10 min prior to the 
addition of the substrate. No difference in IMPase activity was found in these two experiments (data not 
shown). 
IMPase activity in mouse brain crude homogenate is not enhanced by mutated human 
recombinant calbindin  
We examined whether a change in the interaction site of calbindin with IMPase will affect calbindin's 
activation of IMPase. Human recombinant calbindin was mutated so that two amino acids in its 
interaction site with IMPase, Asp24 and Asp26, were replaced by alanine. IMPase activity in mouse 
brain crude homogenate was measured in the presence of 20 μM mutated vs. wildtype calbindin. As 
shown in Figure 3, differently from wildtype calbindin, IMPase activity was not enhanced by 20 μM 
mutated calbindin [ANOVA F2, 14 = 21.8, p<0.001; post-hoc analysis: the activity in the presence of 
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wildtype calbindin was significantly different from both the control (p<0.001) and the activity in the 
presence of mutated calbindin (p<0.001)].  
Specific cyclic and linear pre-cyclic analog peptides inhibit calbindin-activated IMPase  
Out of the two cyclic and two linear pre-cyclic analog peptides (Table 1) cyclic 1 and linear pre-
cyclic analog 1, both with m=4 and n=4 (Scheme 1) significantly reduced calbindin's activation of 
IMPase (Figure 4). 
Enhanced metabolic stability of cyclic peptide 1 
Comparison of the stability of cyclic peptide 1 with that of linear peptide 1 revealed that cyclic 
peptide 1 maintained 50% of its initial amount after 60 minutes of incubation with BBMVs while its 
linear analog was completely degraded after 5 minutes. The enhanced stability contributed by 
cyclization adds "drug like" properties required for further development for potential clinical utilization 
(30). 
Peptide 1 but not peptide 5 exhibited an in-vivo antidepressant-like effect in the FST 
We examined the behavioral effect of two linear peptides [(Peptide 1 (IKEKYP) derived from the 12 
amino-acid sequence reported to interact with calbindin (13) and peptide 5 (SYEHKP) lacking the Lys-
Glu-Lys motif] in the lithium-sensitive animal model of depression, the FST. Intracerebroventricular 
(ICV)  administration of 50 nmoles of peptide 1 in liposomes to mice three hours prior to testing resulted 
in significantly less immobility compared with mice treated with either peptide 5 in liposomes or with 
aCSF in liposomes [mean immobility time: peptide 1, n=13, 40 sec ± 14 (SEM); peptide 5, n=5, 125 ± 
38; aCSF, n=8, 94 ± 25; ANOVA, F3, 27 = 4.5, p=0.01, posthoc LSD test, peptide 1 vs. peptide 5, p=0.01; 
peptide 1 vs. aCSF, p=0.054]. As expected, imipramine-treated mice (positive control) were significantly 
less immobile compared with aCSF-treated or peptide 5-treated mice (n=5, 10 ± 7; p=0.02 and p=0.005, 
respectively) (Figure 5). 
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Discussion 
IMPase, a critical enzyme for brain cell signaling (26: Atack, 1995 #624, 31), is activated by 
calbindin (13), a ubiquitous protein (32-34) constituting about 1% of brain protein content (35). 
Lithium, a mainstay treatment in bipolar disorder, inhibits IMPase at therapeutically-relevant 
concentrations. This inhibition is among the hypotheses of the molecular mechanism of lithium's 
therapeutic action (7). Since lithium has significant limitations and since repeated efforts by several 
drug companies to develop alternative IMPase inhibitors directed to the catalytic site of the enzyme 
were non-successful (11, 12, 31) we studied the possibility to inhibit IMPase activity by targeting 
another site, namely, the site through which it is being activated by calbindin. This was based on the 
assumption that in-vivo, in neurons of particular brain sub-regions (36) implicated to be involved in 
mood regulation (16, 17) and where calbindin is abundant, calbindin's interaction with IMPase enhances 
the enzyme activity. 
Interfering with protein-protein interaction is a new paradigm in drug discovery for neurological 
and psychiatric disorders (37, 38). Small molecule inhibitors designed within this concept include short 
peptides (39). To rationally design short peptides as potential competitive inhibitors of calbindin-
activated IMPase we modeled in silico the structure of the IMPase-calbindin complex by docking the 
NMR structure of calbindin (40) to the crystal structure of bovine IMPase (41).  The model suggested 
that out of the 12 amino acid segment of IMPase which interacts with calbindin (residues 55-66) (13) 
two IMPase residues, Lys59 and Lys61, are hydrogen bonded to calbindin. The residue in between these 
two lysine residues, Glu70, also participates in the interaction with calbindin. The two lysine residues 
interacting with two aspartate residues of calbindin (Asp24 and Asp26) are among the central six amino 
acids of the 12 amino acid segment which is conserved between human and mouse IMPase.  
We experimentally assessed the role of the Lys-Glu-Lys motif of IMPase and the role of Asp24 
and Asp26 of calbindin in the interaction between the two proteins by assessing the inhibitory effect of 
different peptides on the enhancement of mouse brain crude homogenate IMPase activity by wildtype or 
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mutated human recombinant calbindin. The inhibitory effect of the linear peptides 2 through 4 (Table 1) 
on calbindin's activation of IMPase was comparable to that of the 6-mer peptide composed of an 
identical sequence as residues 58-63 of IMPase (peptide 1; Table 1) as long as the permutated peptide 
included the Lys-Glu-Lys motif, or at least a part of it. Nonetheless, five amino acid peptides which 
included a Lys-X-Lys motif but lacked the C-terminal proline residue (peptides 9 and 10; Table 1) did 
not inhibit the activation of IMPase by calbindin indicating a requirement for this specific carboxyl 
terminal residue. A three amino acid peptide comprised of the Lys-Glu-Lys motif only (peptide 11; 
Table 1) also did not inhibit IMPase activation by calbindin. This result suggests that the Lys-Glu-Lys 
motif, or part of it, is necessary but not sufficient for the peptide to inhibit calbindin's activation of 
IMPase and defines a size constraint of at least six amino acids required to inhibit the activation of 
IMPase by calbindin. A similar result of gradual decreased length of an inhibitory peptide affecting its 
potency was observed for peptides inhibiting polyglutamine protein aggregation and cell death in 
neurodegenerative diseases including Huntington’s disease (42). To further evaluate the validity of our 
in silico model we assessed the role of calbindin's Asp24 and Asp26 residues in the interaction with 
IMPase using a mutated calbindin in which both of these aspartate residues were mutated into alanine. 
Unlike wildtype calbindin the mutated calbindin did not activate IMPase. This result supports the 
model's implication that these two aspartate residues of calbindin play a significant role in the 
interaction of the protein with IMPase. 
Berggard et al. (13) found ~100 fold increase of IMPase activity in the presence of calbindin in 
an assay with pure proteins and at an extremely low substrate concentration (2.5 μM) and ~2-3 fold 
increase at a physiologically-relevant substrate concentration (80 μM). Similarly to Berggard et al. (13, 
18), we have previously reported (23) about 3 fold increase of IMPase activity in postmortem human 
brain homogenate in the presence of recombinant human calbindin, a finding replicated in the present 
study. Using mouse brain crude homogenate and recombinant human calbindin, the increase of IMPase 
activity was of about 2 fold. It is conceivable that the difference in the extent of activation of mouse 
brain IMPase by calbindin stems from lower compatibility between mouse IMPase and human 
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calbindin. Indeed, sequence alignment of the full 55-66 segment reveals two amino acid differences 
between human and mouse IMPase. Ile55 and Ser64 in human IMPase are replaced in the mouse 
IMPase by methionine and cysteine, respectively. 
The biochemical results support the suggested molecular mode of interaction between calbindin and 
IMPase and provide a proof of concept for the possibility to inhibit IMPase activity at a site different 
than that of lithium. The next step was to search for a behavioral proof of concept. To this end we 
compared the effect of ICV administration of peptide 1 vs. peptide 5 (Table 1) on the forced swim test 
in mice. We hypothesized that similarly to lithium peptide 1 but not peptide 5 will exhibit an 
antidepressant-like reduction of immobility (43, 44). Our results confirmed our hypothesis and provided 
an in vivo behavioral proof of concept for the novel site through which it may become possible to design 
novel mood stabilizers.  
The use of peptides as drugs endures both advantages and disadvantages. Although peptides are 
highly selective, can be synthetically produced and optimized, in vivo they exhibit short half-lives, poor 
bioavailability and decreased cell permeability, limiting their use in the clinics  (45, 46). This may be 
due to lack of solubility, rapid enzymatic degradation by the intestinal proteolytic enzymes or poor 
intestinal permeability. Different pharmaceutical and chemical approaches were developed to enhance 
oral bioavailability of peptides while maintaining their pharmacological activity. Peptide cyclization or 
blocking their N- and C-terminal amino acids has been shown to address these limitations rendering the 
peptides to exhibit increased potency, increased stability to proteolytic degradation and enable their 
binding to the target at decreased effective concentrations (47, 48). In the present study the cycloscan 
and backbone cyclization methods (29, 30, 49) were used to circumvent the problems that hamper the 
conversion of peptides into drugs. Utilizing cyclic or linear pre-cyclic analog peptides in which the 
pharmacophors are preserved in the same sequence and constitution as in the parent peptide 1 we were 
able to mimic peptide 1's inhibitory effect on the activation of IMPase by calbindin in vitro. The 
enhanced stability of cyclic peptide 1 compared with it's linear analog adds "drug like" property 
required for further development for potential clinical utilization (30). 
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Obviously, further studies should investigate whether cyclic or linear pre-cyclic peptides 
modified to exhibit membrane permeability and biological stability (48), or nonpeptide small molecules 
(38) based on our in silico model, can mimic behavioral effects of lithium in inositol-related paradigms 
(50, 51) or other lithium-induced behavioral effects in animals (52). 
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Table 1: Synthetic peptides 
IKEKYP   peptide 1 composed of an identical sequence as residues 58-63 of IMPase 
IKAKYP  peptide 2 peptide 1 in which Glu60 was permutated to Ala 
IKEAYP  peptide 3 peptide 1 in which Lys61 was permutated to Ala 
IAEKYP  peptide 4 peptide 1 in which Lys59 was permutated to Ala 
SYEHKP peptide 5 
peptide 1 in which Ile58 and Lys61 were permutated to histidine 
and serine, respectively, and the whole sequence has been 
scrambled  
IAEAYP  peptide 6 
peptide 1 in which both Lys59 and Lys61 were permutated to 
Ala 
IAAAYP  peptide 7 
peptide 1 in which the whole Lys-Glu-Lys motif has been 
permutated to three Ala residues 
KHIKPS  peptide 8 
a random 6-mer peptide containing two lysine residues albeit, 
separated by two, rather than a single residue, none of which 
was glutamate 
 IKEKY   peptide 9 
5-mer peptide lacking the carboxyterminal Pro and including the 
Lys-Glu-Lys motif 
IKAKY peptide 10 
5-mer peptide lacking the carboxyterminal Pro and including a 
Lys-Ala-Lys replacement 
 KEK   peptide 11 the Lys-Glu-Lys motif only 
Linear pre-cyclic analog 1 
based on peptide1 
(see Scheme 1) 
Cyclic 1 
Linear pre-cyclic analog 2 
Cyclic 2 
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Figure legends 
Figure 1: Three dimensional structure of IMPase (a) and the modeled complex of IMPase and 
calbindin (b)    
a. The crystal structure of IMPase shown as a green ribbon, residues 55-66 are colored in 
purple and the central six amino acids (residues 58-63) are colored in red. Magnesium ions at 
the active site are shown as blue balls; the side chain of Glu70 at the active site is shown in 
yellow.  
b. The docking model of IMPase (in green) and calbindin (in blue). Calcium ions are shown 
as orange balls. The side chains of possible interacting residues are shown as sticks (Lys59 
and Lys61 of IMPase - in magenta and Asp24 and Asp26 of calbindin - in yellow). 
The figure was produced using the program PyMol. 
 
 
Figure 2: The effect of linear peptides on calbindin-activated IMPase activity  
Results are means + S.E.M. 
A. The effect of six amino acid linear peptides containing the Lys-Glu-Lys motif or part of it (see 
Table 1)   
ANOVA: F(5, 74)=3.28, p=0.01 
Post hoc LSD test: 
* control vs. calbindin, p<0.001 
** calbindin vs. peptide 1, p=0.008,  
** calbindin vs. peptide 2, p=0.001 
** calbindin vs. peptide 3, p=0.03 and peptide 4, p=0.02 
 
B. The effect of six amino acid linear peptides which include only one or none of the amino acids Lys 
or Glu of the Lys-Glu-Lys motif compared to peptide 1 (see Table 1)   
ANOVA: F(6, 55)=1.8, p=0.11 
Post hoc LSD test: 
* control vs. calbindin, p=0.01 
** calbindin vs. peptide 1, p=0.007 
 
C. The effect of two five amino acid peptides (peptides 9 and 10) and a three amino acid peptide 
containing the Lys-Glu-Lys motif or a Lys-Ala-Lys replacement compared with peptide 1 (see 
Table 1)   
ANOVA: F(5, 50)=3.79, p=0.005 
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Post hoc LSD test: 
* control vs. calbindin, p=0.002, 
 ** calbindin vs. peptide 1,  p<0.001 
 
Figure 3: Mutated calbindin in which Asp24 and Asp26 were mutated to Ala did not activate 
IMPase  
Results are means + S.E.M.; n=5 in all groups 
 
ANOVA: F(2,14)=21.8, p<0.001 
Post-hoc LSD test:  
wildtype calbindin vs. control, p<0.001  
wildtype calbindin vs. mutated calbindin, p<0.001 
 
Figure 4: The effect of cyclic or linear pre-cyclic analog (LPCA) peptides on calbindin-activated 
IMPase activity  
Results are means + S.E.M. 
  Student's t-tests:   
  #  calbindin vs. control, p<0.0001 
  *   peptide 1 vs. calbindin, p< 0.001  
  ** LPCA-1 and Cyclic-1 vs. calbindin, p< 0.05 
 
Figure 5: Peptide 1 (IKEKYP) exhibits an antidepressant-like effect in the forced swim test  
   Results are mean + S.E.M. 
ANOVA, F3,27=4.52, p=0.011 
Post-hoc LSD test: 
* peptide 1 vs. aCSF, p=0.05, and vs. peptide 5, p=0.01                                
** Positive control, imipramine vs. aCSF, p=0.02 
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